The Efficacy of Remdesivir Drug to Control the Recently Emerged Novel Severe Acute Respiratory Syndr

Remdesivir is one of the investigational medications that has shown some promise against COVID-19, possibly due to its broad-spectrum antiviral activity against several RNA viruses. There have been very few clinical investigations on the use of remdesivir in the treatment of COVID-19 to yet. The primary goal of this study was to conduct a review of Remdesivir's effectiveness in the treatment of COVID-19. To our knowledge, this is the first systematic review of the effect of the remdesivir medication on COVID-19 treatment. Methodology: We searched PubMed for papers that evaluated the effect of the remdesivir medication in patients with confirmed COVID-19. “COVID-19” or “SARS-CoV-2,” “remdesivir,” and “systematic review” were the most common search phrases.

In this comprehensive review, only 11 research publications were identified to be appropriate for inclusion, and only two of those studies were randomised, placebo-controlled trials of intravenous remdesivir. Results from clinical Phase-III trials on the efficacy of remdesivir in patients with confirmed COVID-19 are currently forthcoming. In the later half of May, the results of two hospital-based randomised, double-blind, placebo-controlled trials were released. Remdesivir was proven to be effective in the treatment of patients with confirmed COVID-19 in two placebo-controlled phase III clinical studies. Wang et al. (2020) discovered, however, that remdesivir therapy was not related with clinical benefits.

Conclusion: The use of remdesivir to cure patients with severe COVID-19 was determined to be promising in the systematic review; nevertheless, more clinical studies with large patient populations are needed. Future research studies will need to stress the efficacy and safety of remdesivir in the treatment of COVID-19.

Please see the link :- https://www.journaljamb.com/index.php/JAMB/article/view/30294